Mira Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Mira Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Mira Pharmaceuticals Inc recorded a cumulative net loss of $-9 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -104.19%.

However, within the Healthcare sector 747 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4367, from total ROA ranking in the first quarter of 2026 at 5181.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	844.7 %	575.8 %	279.52 %	78.91 %	-71.2 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-9	-10	-10	-7	-8
Return On Assets (TTM)	-104.19 %	-135.02 %	-198.95 %	-213.92 %	-328.39 %
MIRA's Total Ranking	# 4367	# 5181	# 4610	# 4768	# 4804
Total Assets (TTM) in million	8	9	11	8	1
Seq. Total Assets Change	-13.32 %	-14.69 %	45.33 %	779.07 %	-37.99 %
Seq. Net Income Change	-	-	-	-	-

MIRA's 5 Years Annual ROA >> Back to MIRA Management Effectiveness >> Compare MIRA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 347
Sector	# 748
Overall	# 4237

Return On Assets Statistics
High	Average	Low
-14.95 %	-144.94 %	-328.39 %
(Sep 30 2024)		(Jun 30 2025)

Financial Statements
Mira Pharmaceuticals Inc 's Assets	$ 8 million	MIRA's Balance sheet
Mira Pharmaceuticals Inc 's Income	$ -1 million	Quarterly MIRA's Income Statement
MIRA's Income by Division		See MIRA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	FY	FY
Y / Y Total Assets Change	279.52 %	-40.74 %	-	-	-
Total Assets in million	11	3	5	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-10	-8	-12	0	0
Annual Return On Assets	-94.13 %	-268.64 %	-242.93 %	-	-

MIRA's 5 Years Annual ROA >> Back to MIRA Management Effectiveness >> Compare MIRA ROA to its Competitors

More Return On Assets Ratios
MIRA's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
MIRA's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for MIRA's Competitors
Subscribers only: Roa for Mira Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for MIRA's Customers

You may also want to know
MIRA's Roi	MIRA's Inventory Turnover Ratio	MIRA's Growth Rates	MIRA's Dividend Comparisons
	MIRA's Profitability Ratios	MIRA's Asset Turnover Ratio	MIRA's Dividend Growth
MIRA's Roe	MIRA's Valuation Ratios	MIRA's Financial Strength Ratios	MIRA's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-03T16:20:42+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.